Healthcare - Press Releases

ZURICH, March 19, 2025 /PRNewswire/ -- ArisGlobal, a leading life sciences technology company and creator of LifeSphere, today announced three new cutting-edge product offerings that will advance pharmacovigilance and regulatory operations. At Breakthrough 2025, its annual industry event, the company unveiled LifeSphere Unify, NavaX Insights, and Advanced Compliance Docs.

ZURICH, March 19, 2025 /PRNewswire/ -- ArisGlobal, a leading life sciences technology company and creator of LifeSphere, today announced three new cutting-edge product offerings that will advance pharmacovigilance and regulatory operations. At Breakthrough 2025, its annual industry event, the company unveiled LifeSphere Unify, NavaX Insights, and Advanced Compliance Docs.

Strategic agreement to deploy Lunit INSIGHT MMG across SEHA's extensive healthcare network, analyzing over hundred thousand mammograms over five years

Daxko partners with Bloomerang to release a new integration that will enrich member information with giving data from Bloomerang.

Real-time data access and expert guidance helped GrandCare prevent layoffs and enhance care efficiency.

El New York StateWide Senior Action Council's"Fraude de Medicare del mesparamarzo"

New Initiative Part of Company's Mission to Move OrganizationsAcross the Healthcare Ecosystem to a More Secure, Compliant, and Resilient State So They Can Achieve Their Mission

CHICAGO, March 18, 2025 /PRNewswire/ -- This year the National Certification Corporation (NCC) Celebrates 50 years of service to the community of obstetric, neonatal and women's healthcare professionals by providing a Second Chance Free Examination Promotion. The importance of the certified healthcare community and the care they provide cannot be overstated!

BOSTON, MA and ROLLE, Switzerland, March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data.

NEW YORK, March 18, 2025 /PRNewswire/ -- Remedy Pharmaceuticals, a leader in stroke drug development, today announced that the U.S. Patent and Trademark Office (USPTO) has allowed two additional patents covering its large hemispheric infarction (LHI) drug, CIRARA (IV glyburide).

Presence and Move This World partner to help districts to improve alignment in Multi-Tiered Systems of Support to better support students

ClassPass releases 5th annual Best of ClassPass Awards, honoring the top fitness & wellness businesses around the world

BEAUTY SLEEP ON REPEAT - WAKE UP TO BETTER SKIN, NIGHT AFTER NIGHT

Revolutionary System as a Service (SYaaS) model recognized for transforming healthcare IT innovation and implementation

Technology investments will immediately improve administrative efficiency while supporting future public health initiatives

AMES, Iowa, March 18, 2025 /PRNewswire/ --GlobalVetLink (GVL), the leader in digital animal health compliance solutions, has announced a new integration with Provet Cloud, a leading cloud-based veterinary practice management system. This integration streamlines the creation of health certificates and other regulatory compliance documents, reducing administrative burdens and enhancing efficiency for veterinary professionals.

UNITY is the only commercially available non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a single maternal blood draw.

With the introduction of DSai (Digital Sign-In with AI), Groupize gives Life Sciences companies an innovative new technology designed to streamline and digitize attendee management while ensuring compliance and accuracy.

Turpaz sales in the fourth quarter jumped 65% to a record $55 million; adj. EBITDA, which is among the industry leaders, rose to 23% of sales in the fourth quarter, reflecting a 66.7% increase compared to the corresponding quarter; operating profit in the fourth quarter jumped 71% and net profit grew 34.5%

Hamilton Spence Is Among Few Neonatologists Awarded This Specialized Designation

CHAPEL HILL, N.C., March 18, 2025 /PRNewswire/ -- SonoVascular, Inc., a clinical stage medical device company focused on bringing to market its SonoThrombectomySystem for venous thromboembolism (VTE), a novel treatment solution intended to provide better outcomes for millions of patients suffering from deep vein thrombosis (DVT) and pulmonary embolism (PE), has successfully completed an initial set of eight cases in patients with DVT in its First-In-Human (FIH) study.

SaaS solution minimizes manual processes, accelerates batch release cycles and meets regulatory compliance*

SAN JOSE, Calif., March 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive Officer, Dr. Amit Kumar, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans.

Bracco Diagnostics Inc. (PRNewsFoto/Bracco Diagnostics Inc.) (PRNewsfoto/Bracco Group) HeartSee Logo

NEW YORK, March 17, 2025 /PRNewswire/ --GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for its investigational drug,radiprodil, for the treatment of GRIN-related neurodevelopmental disorder (NDD). Radiprodil is designed as a potent negative allosteric modulator selectively targeting the N-methyl-D-aspartate receptor subtype 2B (NR2B or GluN2B). The company is on track to initiate a pivotal Phase 3 trial for radiprodil in mid-2025 for the treatment of GRIN-related NDD with GoF mutations and has an ongoing global open-label clinical trial of radiprodil for the treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II.